HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

N-acetyltalosaminuronic acid (NAT)

partially comprises saccharide frame of pseudomurein; structure given in first source
Also Known As:
NAT; TalANAc; alpha-L-2-N-acetylamino-2-desoxytaluronic acid; alpha-L-N-acetyltalosaminuronic acid; alpha-L-Talopyranuronic acid, 2-(acetylamino)-2-deoxy-, (5Z,11alpha,13E,15S)-
Networked: 2187 relevant articles (143 outcomes, 393 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Chung, J G: 20 articles (05/2005 - 01/2000)
2. Stramer, Susan L: 16 articles (11/2022 - 12/2004)
3. Chung, Jing-Gung: 16 articles (03/2006 - 01/2003)
4. Hung, C F: 16 articles (09/2002 - 01/2000)
5. Lelie, Nico: 14 articles (01/2022 - 05/2006)
6. Busch, Michael P: 12 articles (10/2020 - 08/2003)
7. Mairs, Robert J: 11 articles (11/2016 - 02/2005)
8. Boyd, Marie: 10 articles (11/2013 - 02/2005)
9. Laperche, Syria: 9 articles (01/2022 - 07/2003)
10. Bahary, Nathan: 8 articles (11/2021 - 10/2017)

Related Diseases

1. Neoplasms (Cancer)
10/01/2016 - "These alterations occurred in a subtype-dependent manner, suggesting that NAT may have either eliminated the most susceptible tumor subclone, leaving the treatment resistant clone with a different genetic signature, or altered molecular characteristics of the original cancer."
01/01/2022 - "This study aims to explore the relationship between peripheral blood lymphocytes (PBLs) subsets distribution and the efficacy of NAT. Between December 2017 and March 2021, a total of 116 BC patients appropriate for NAT in Sun Yat-Sen University cancer center were enrolled, pre-NAC baseline blood samples were taken for further flow cytometry analysis to quantitatively evaluate the PBLs subsets distribution, and corresponding clinical information including pathological complete response (pCR) rate of NAT response were recorded. "
09/08/2023 - "Conclusions: HER2 copy numbers, HER2 immunohistochemical expression level, molecular subtype, ER expression level and Ki-67 proliferation index are significantly associated with pCR after NAT. In addition, fluorescence in situ hybridization results, HER2/CEP17 ratio and tumor size could also significantly affect the efficacy of NAT. 目的: 探讨与HER2阳性乳腺癌新辅助治疗疗效相关的临床病理学特征。 方法: 收集复旦大学附属肿瘤医院病理科2015—2020年诊断的接受新辅助治疗的HER2阳性乳腺癌480例,分析临床病理参数如年龄、肿瘤大小、分子分型、靶向治疗类型、Ki-67阳性指数、雌激素受体(ER)表达水平、HER2免疫组织化学表达水平及HER2扩增情况等与患者新辅助治疗疗效的相关性。 结果: 480例HER2阳性乳腺癌患者中209例在新辅助治疗后达到病理完全缓解(pathology complete response,pCR),pCR率达43.5%。所有病例中457例患者接受化疗加单靶(曲妥珠单抗)治疗,23例患者接受化疗加双靶(曲妥珠单抗+帕妥珠单抗)治疗。化疗加单靶治疗中198例(43.3%)获得pCR,而化疗加双靶治疗中11例(47.8%)达到pCR。后者的pCR率相对较高,但两者差异无统计学意义。结果显示免疫组织化学HER2 3+(49.0%)患者的pCR率显著高于HER2 2+患者(26.1%,P<0.001)。荧光原位杂交(FISH)检测中HER2平均拷贝数越高,pCR率也越高。ER的表达水平与新辅助治疗疗效呈负相关,ER阳性组(28.2%)的pCR率显著低于ER阴性组(55.8%,P<0.001)。Luminal B型(29.1%)乳腺癌患者的pCR率低于HER2过表达型(55.8%),且差异有统计学意义(P<0.001)。另外,高Ki-67阳性指数与高pCR率相关(P<0.001)。肿瘤≤2 cm组的pCR率(57.7%)最高,而肿瘤>5 cm组的pCR率(31.1%)最低,且组间差异有统计学意义(P=0.005)。 结论: HER2拷贝数、HER2免疫组织化学表达水平、分子分型、ER表达情况及Ki-67阳性指数与新辅助治疗后是否达到pCR具有显著相关性。此外,FISH结果分组、HER2/CEP17比值及肿瘤大小也可显著影响新辅助治疗疗效。."
03/27/2021 - "NAT can cause tumor downstaging preoperatively or even complete remission of the primary tumor. "
10/20/2022 - "Pathological response to NAT has been associated with improved patients' survival; however, the current techniques employed for assessing the tumor response have significant limitations. "
2. Infections
3. Breast Neoplasms (Breast Cancer)
4. Pancreatic Neoplasms (Pancreatic Cancer)
5. Adenocarcinoma

Related Drugs and Biologics

1. Nucleic Acids
2. Hepatitis B Surface Antigens (HBsAg)
3. Natalizumab (Tysabri)
4. DNA (Deoxyribonucleic Acid)
5. Trastuzumab (Herceptin)
6. 130-nm albumin-bound paclitaxel
7. 3-Iodobenzylguanidine (Iobenguane)
8. Proteins (Proteins, Gene)
9. Biomarkers (Surrogate Marker)
10. Tryptophan (L-Tryptophan)

Related Therapies and Procedures

1. Neoadjuvant Therapy
2. Therapeutics
3. Radiotherapy
4. Donor Selection
5. Blood Transfusion (Blood Transfusions)